| Title |
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL
|
|---|---|
| Published in |
SpringerPlus, January 2014
|
| DOI | 10.1186/2193-1801-3-5 |
| Pubmed ID | |
| Authors |
Karin Hohloch, Carsten Zwick, Marita Ziepert, Dirk Hasenclever, Ulrich Kaiser, Andreas Engert, Heinz-Gert Höffkes, Frank Kroschinsky, Rolf Mesters, Andreas C Feller, Markus Löffler, Lorenz Trümper, Michael Pfreundschuh |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 15 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 33% |
| Student > Bachelor | 3 | 20% |
| Professor | 1 | 7% |
| Other | 1 | 7% |
| Student > Master | 1 | 7% |
| Other | 3 | 20% |
| Unknown | 1 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 47% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 13% |
| Business, Management and Accounting | 1 | 7% |
| Immunology and Microbiology | 1 | 7% |
| Nursing and Health Professions | 1 | 7% |
| Other | 2 | 13% |
| Unknown | 1 | 7% |